› Forums › General Melanoma Community › Dr. Ribas Adoptive Cell Therapy with a new twist.
- This topic has 5 replies, 4 voices, and was last updated 4 years, 2 months ago by ScaredPartner.
- Post
-
- February 4, 2020 at 4:06 pm
When melanoma patients choose TIL’s they normally get IL-2 after chemo depletion to rev the immune system up so that when they get the TIL’s infusion, the IL-2 will help prime the immune system so the T-cell will get into the melanoma tumor cells. NKTR-214 has been in clinical trial (Pivot 02 trial) for a couple of years in combination with Pd-1 Nivolumab. They now called NKTR-214 “Bempegaldesleukin” which is old school IL-2 with a twist of being pegylated which reduces the toxicity compared with old school IL-2. Now, while we are still waiting for data on NKTR-214 + nivo to see if early trial results hold up, it does make sense to use it in TIL’s. Here is a new research article from UCLA and Dr. Ribas, where they are developing a new twist to TIL’s and hopefully in the near future it will be available for those who fail Immunotherapy or targeted therapy or maybe even a first line treatment approach one day. https://cancer.ucla.edu/Home/Components/News/News/1442/1631
Viewing 2 reply threads
- Replies
-
-
- February 4, 2020 at 4:08 pm
For anyone interested in NKTR-214 in more detail, Dr. Adi Diab of MD Anderson explains things on Onclive in following video. https://www.onclive.com/inside-oncology/solid-tumor-pivot02/the-pivot02-trial-nktr214-with-nivolumab-
- February 4, 2020 at 4:09 pm
Here is video from youtube so you can avoid Onclive block. https://www.youtube.com/watch?time_continue=21&v=kvyPL5W9ZTA&feature=emb_logo
-
-
- February 7, 2020 at 1:40 am
Thank you for sharing. I love seeing new hope. Now the key is living long enough to get to a trial on this.
-
Viewing 2 reply threads
- You must be logged in to reply to this topic.